{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:59:11Z","timestamp":1789675151606,"version":"4.0.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>A systematic literature review was conducted to summarize efficacy and safety data from studies that evaluated tumor necrosis factor inhibitors in patients with juvenile idiopathic arthritis (JIA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Relevant publications were identified via online searches (cutoff: March 16, 2021). After screening search results, outcome data were extracted if the treatment arm included\u2009\u2265\u200930 patients. Outcomes were described narratively, with efficacy assessed by JIA-American College of Rheumatology (ACR) response criteria and safety assessed by the incidence of serious adverse events (SAEs) per 100 patient-years (100PY).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 87 relevant publications included in the qualitative synthesis, 19 publications described 13 clinical trials. Across the 13 trials, the percentages of patients who achieved JIA-ACR30\/50\/70\/90 responses at Week 12 with adalimumab ranged 71\u201394%, 68\u201390%, 55\u201361%, and 39\u201342%, respectively; with etanercept (Week 12), 73\u201394%, 53\u201378%, 36\u201359%, and 28%; with golimumab (Week 16), 89%, 79%, 66%, and 36%; and with infliximab (Week 14), 64%, 50%, and 22% (JIA-ACR90 not reported). SAE incidence across all time points ranged 0\u201313.7 SAE\/100PY for adalimumab, 0\u201320.0 SAE\/100PY for etanercept, and 10.4\u201324.3 SAE\/100PY for golimumab (1 study). SAE incidence could not be estimated from the 2 infliximab publications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tumor necrosis factor inhibitors are effective and well tolerated in the treatment of JIA, but additional evidence from head-to-head studies and over longer periods of time, especially in the context of the transition from pediatric to adult care, would be useful.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12969-023-00798-8","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T06:03:18Z","timestamp":1677218598000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy and safety of TNF inhibitors in the treatment of juvenile idiopathic arthritis: a systematic literature review"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5491-7832","authenticated-orcid":false,"given":"Gerd","family":"Horneff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Minden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana C. Hernandez","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Borlenghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolino","family":"Ruperto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,24]]},"reference":[{"issue":"2","key":"798_CR1","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132.","journal-title":"J Rheumatol"},{"issue":"7","key":"798_CR2","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.3899\/jrheum.120661","volume":"40","author":"LR Harrold","year":"2013","unstructured":"Harrold LR, Salman C, Shoor S, Curtis JR, Asgari MM, Gelfand JM, et al. Incidence and prevalence of juvenile idiopathic arthritis among children in a managed care population, 1996\u20132009. J Rheumatol. 2013;40(7):1218\u201325.","journal-title":"J Rheumatol"},{"issue":"2","key":"798_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jbspin.2013.09.003","volume":"81","author":"S Thierry","year":"2014","unstructured":"Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine. 2014;81(2):112\u20137.","journal-title":"Joint Bone Spine"},{"issue":"1","key":"798_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/art.39323","volume":"68","author":"ML Krause","year":"2016","unstructured":"Krause ML, Crowson CS, Michet CJ, Mason T, Muskardin TW, Matteson EL. Juvenile idiopathic arthritis in Olmsted County, Minnesota, 1960\u20132013. Arthritis Rheumatol. 2016;68(1):247\u201354.","journal-title":"Arthritis Rheumatol"},{"issue":"9563","key":"798_CR5","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","volume":"369","author":"A Ravelli","year":"2007","unstructured":"Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767\u201378.","journal-title":"Lancet"},{"key":"798_CR6","doi-asserted-by":"publisher","first-page":"P50","DOI":"10.1186\/1546-0096-6-S1-P50","volume":"6","author":"I Nikishina","year":"2008","unstructured":"Nikishina I, Shapovalenko A. Growth retardation in patients with juvenile idiopathic arthritis and growth hormone therapy. Pediatr Rheumatol. 2008;6:P50.","journal-title":"Pediatr Rheumatol"},{"issue":"9783","key":"798_CR7","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","volume":"377","author":"B Prakken","year":"2011","unstructured":"Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377(9783):2138\u201349.","journal-title":"Lancet"},{"issue":"5","key":"798_CR8","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrrheum.2011.38","volume":"7","author":"A Hersh","year":"2011","unstructured":"Hersh A, von Scheven E, Yelin E. Adult outcomes of childhood-onset rheumatic diseases. Nat Rev Rheumatol. 2011;7(5):290\u20135.","journal-title":"Nat Rev Rheumatol"},{"key":"798_CR9","first-page":"20","volume":"72","author":"K Minden","year":"2009","unstructured":"Minden K. Adult outcomes of patients with juvenile idiopathic arthritis. Horm Res. 2009;72:20\u20135.","journal-title":"Horm Res"},{"issue":"5","key":"798_CR10","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/acr.23327","volume":"70","author":"A Tollisen","year":"2018","unstructured":"Tollisen A, Selvaag AM, Aulie HA, Lilleby V, Aasland A, Lerdal A, et al. Physical functioning, pain, and health-related quality of life in adults with juvenile idiopathic arthritis: a longitudinal 30-year followup study. Arthritis Care Res (Hoboken). 2018;70(5):741\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"798_CR11","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/acr.23870","volume":"71","author":"S Ringold","year":"2019","unstructured":"Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML, et al. 2019 American College of Rheumatology\/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Care Res (Hoboken). 2019;71(6):717\u201334.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"798_CR12","first-page":"819","volume":"77","author":"A Ravelli","year":"2018","unstructured":"Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018;77(6):819\u201328.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"798_CR13","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"DJ Lovell","year":"2000","unstructured":"Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000;342(11):763\u20139.","journal-title":"N Engl J Med"},{"issue":"9","key":"798_CR14","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1002\/art.22838","volume":"56","author":"N Ruperto","year":"2007","unstructured":"Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56(9):3096\u2013106.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"798_CR15","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810\u201320.","journal-title":"N Engl J Med"},{"issue":"4","key":"798_CR16","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1136\/ard.2009.100354","volume":"69","author":"N Ruperto","year":"2010","unstructured":"Ruperto N, Lovell DJ, Cuttica R, Woo P, Meiorin S, Wouters C, et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis. 2010;69(4):718\u201322.","journal-title":"Ann Rheum Dis"},{"key":"798_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1546-0096-8-24","volume":"8","author":"S Visvanathan","year":"2010","unstructured":"Visvanathan S, Wagner C, Marini JC, Lovell DJ, Martini A, Petty R, et al. The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial. Pediatr Rheumatol Online J. 2010;8:24.","journal-title":"Pediatr Rheumatol Online J"},{"key":"798_CR18","first-page":"947","volume":"68","author":"HI Brunner","year":"2016","unstructured":"Brunner HI, Ruperto N, Keltsev V, Alexeeva E, Abud-Mendoza C, Schmeling H, et al. A multi-center, open-label study to assess the pharmacokinetics, efficacy and safety of certolizumab pegol in children and adolescents with moderately to severely active polyarticular-course juvenile idiopathic arthritis: week 24 results [abstract]. Arthritis Rheumatol. 2016;68:947.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"798_CR19","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s13075-016-1170-3","volume":"18","author":"G Horneff","year":"2016","unstructured":"Horneff G, Klein A, Klotsche J, Minden K, Huppertz HI, Weller-Heinemann F, et al. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. Arthritis Res Ther. 2016;18(1):272.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"798_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/annrheumdis-2016-210456","volume":"77","author":"HI Brunner","year":"2018","unstructured":"Brunner HI, Ruperto N, Tzaribachev N, Horneff G, Chasnyk VG, Panaviene V, et al. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis. 2018;77(1):21\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"798_CR21","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1080\/14740338.2019.1632288","volume":"18","author":"C Diener","year":"2019","unstructured":"Diener C, Horneff G. Comparison of adverse events of biologicals for treatment of juvenile idiopathic arthritis: a systematic review. Expert Opin Drug Saf. 2019;18(8):719\u201332.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"798_CR22","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.semarthrit.2012.10.006","volume":"42","author":"WJ Ungar","year":"2013","unstructured":"Ungar WJ, Costa V, Burnett HF, Feldman BM, Laxer RM. The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review. Semin Arthritis Rheum. 2013;42(6):597\u2013618.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"798_CR23","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.semarthrit.2016.07.001","volume":"46","author":"G Amarilyo","year":"2016","unstructured":"Amarilyo G, Tarp S, Foeldvari I, Cohen N, Pope TD, Woo JM, et al. Biological agents in polyarticular juvenile idiopathic arthritis: a meta-analysis of randomized withdrawal trials. Semin Arthritis Rheum. 2016;46(3):312\u20138.","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"798_CR24","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/rheumatology\/kev382","volume":"55","author":"S Tarp","year":"2016","unstructured":"Tarp S, Amarilyo G, Foeldvari I, Christensen R, Woo JM, Cohen N, et al. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. Rheumatology (Oxford). 2016;55(4):669\u201379.","journal-title":"Rheumatology (Oxford)"},{"issue":"34","key":"798_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20340","volume":"20","author":"J Shepherd","year":"2016","unstructured":"Shepherd J, Cooper K, Harris P, Picot J, Rose M. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2016;20(34):1\u2013222.","journal-title":"Health Technol Assess"},{"issue":"5","key":"798_CR26","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.semarthrit.2016.10.008","volume":"46","author":"R Davies","year":"2017","unstructured":"Davies R, Gaynor D, Hyrich KL, Pain CE. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: a systematic review. Semin Arthritis Rheum. 2017;46(5):584\u201393.","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"798_CR27","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1093\/rheumatology\/keaa170","volume":"59","author":"N Cabrera","year":"2020","unstructured":"Cabrera N, Avila-Pedretti G, Belot A, Larbre JP, Mainbourg S, Duquesne A, et al. The benefit-risk balance for biological agents in juvenile idiopathic arthritis: a meta-analysis of randomized clinical trials. Rheumatology (Oxford). 2020;59(9):2226\u201336.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"798_CR28","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","volume":"62","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1-34.","journal-title":"J Clin Epidemiol"},{"key":"798_CR29","unstructured":"Rolland C, Lucas S, Horneff G, Ruperto N, Minden K, Curiale C, et al. Assessing the clinical effectiveness and safety of tumour necrosis factor inhibitors (TNFis) for juvenile idiopathic arthritis in the transition from pediatric to adult rheumatology: a systematic review. [Available from: https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42020162694."},{"key":"798_CR30","unstructured":"Cochrane. Risk of Bias 2 (RoB 2) tool [Available from: https:\/\/methods.cochrane.org\/risk-bias-2."},{"key":"798_CR31","unstructured":"Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [Available from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"issue":"7","key":"798_CR32","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","volume":"40","author":"EH Giannini","year":"1997","unstructured":"Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40(7):1202\u20139.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"798_CR33","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/art.24516","volume":"61","author":"A Consolaro","year":"2009","unstructured":"Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(5):658\u201366.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"798_CR34","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/art.10710","volume":"48","author":"DJ Lovell","year":"2003","unstructured":"Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. 2003;48(1):218\u201326.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"798_CR35","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1002\/art.21885","volume":"54","author":"DJ Lovell","year":"2006","unstructured":"Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein LD, et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2006;54(6):1987\u201394.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"798_CR36","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/art.23427","volume":"58","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58(5):1496\u2013504.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"798_CR37","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1002\/art.34343","volume":"64","author":"CA Wallace","year":"2012","unstructured":"Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O\u2019Neil KM, Zeft AS, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012;64(6):2012\u201321.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"798_CR38","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1136\/annrheumdis-2012-203046","volume":"73","author":"G Horneff","year":"2014","unstructured":"Horneff G, Burgos-Vargas R, Constantin T, Foeldvari I, Vojinovic J, Chasnyk VG, et al. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis. 2014;73(6):1114\u201322.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"798_CR39","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1007\/s10067-014-2498-1","volume":"33","author":"DJ Kingsbury","year":"2014","unstructured":"Kingsbury DJ, Bader-Meunier B, Patel G, Arora V, Kalabic J, Kupper H. Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years. Clin Rheumatol. 2014;33(10):1433\u201341.","journal-title":"Clin Rheumatol"},{"issue":"11","key":"798_CR40","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/acr.22657","volume":"67","author":"R Burgos-Vargas","year":"2015","unstructured":"Burgos-Vargas R, Tse SM, Horneff G, Pangan AL, Kalabic J, Goss S, et al. A randomized, double-blind, placebo-controlled multicenter study of adalimumab in pediatric patients with enthesitis-related arthritis. Arthritis Care Res (Hoboken). 2015;67(11):1503\u201312.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"798_CR41","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1002\/art.39145","volume":"67","author":"G Horneff","year":"2015","unstructured":"Horneff G, Foeldvari I, Minden K, Trauzeddel R, K\u00fcmmerle-Deschner JB, Tenbrock K, et al. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study. Arthritis Rheumatol. 2015;67(8):2240\u20139.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"798_CR42","doi-asserted-by":"publisher","first-page":"816","DOI":"10.3899\/jrheum.150430","volume":"43","author":"T Constantin","year":"2016","unstructured":"Constantin T, Foeldvari I, Vojinovic J, Horneff G, Burgos-Vargas R, Nikishina I, et al. Two-year efficacy and safety of etanercept in pediatric patients with extended oligoarthritis, enthesitis-related arthritis, or psoriatic arthritis. J Rheumatol. 2016;43(4):816\u201324.","journal-title":"J Rheumatol"},{"issue":"1","key":"798_CR43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12969-017-0138-4","volume":"15","author":"PC Hissink Muller","year":"2017","unstructured":"Hissink Muller PC, Brinkman DM, Schonenberg D, Koopman-Keemink Y, Brederije IC, Bekkering WP, et al. A comparison of three treatment strategies in recent onset non-systemic juvenile idiopathic arthritis: initial 3-months results of the BeSt for Kids-study. Pediatr Rheumatol Online J. 2017;15(1):11.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"798_CR44","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13075-019-1916-9","volume":"21","author":"I Foeldvari","year":"2019","unstructured":"Foeldvari I, Constantin T, Vojinovi\u0107 J, Horneff G, Chasnyk V, Dehoorne J, et al. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial. Arthritis Res Ther. 2019;21(1):125.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"798_CR45","doi-asserted-by":"publisher","first-page":"e001208","DOI":"10.1136\/rmdopen-2020-001208","volume":"6","author":"DJ Lovell","year":"2020","unstructured":"Lovell DJ, Brunner HI, Reiff AO, Jung L, Jarosova K, N\u011bmcov\u00e1 D, et al. Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate. RMD Open. 2020;6(2):e001208.","journal-title":"RMD Open"},{"issue":"1","key":"798_CR46","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12969-020-00488-9","volume":"19","author":"E Alexeeva","year":"2021","unstructured":"Alexeeva E, Horneff G, Dvoryakovskaya T, Denisova R, Nikishina I, Zholobova E, et al. Early combination therapy with etanercept and methotrexate in JIA patients shortens the time to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial. Pediatr Rheumatol Online J. 2021;19(1):5.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"10","key":"798_CR47","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1093\/rheumatology\/keab021","volume":"60","author":"N Ruperto","year":"2021","unstructured":"Ruperto N, Brunner HI, Pacheco-Tena C, Louw I, Vega-Cornejo G, Spindler AJ, et al. Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford). 2021;60(10):4495\u2013507.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"798_CR48","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1002\/art.27670","volume":"62","author":"N Ruperto","year":"2010","unstructured":"Ruperto N, Giannini EH, Pistorio A, Brunner HI, Martini A, Lovell DJ. Is it time to move to active comparator trials in juvenile idiopathic arthritis?: a review of current study designs. Arthritis Rheum. 2010;62(11):3131\u20139.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"798_CR49","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/art.42240","volume":"74","author":"MH Chang","year":"2022","unstructured":"Chang MH, Bocharnikov AV, Case SM, Todd M, Laird-Gion J, Alvarez-Baumgartner M, et al. Joint-specific memory and sustained risk for new joint accumulation in autoimmune arthritis. Arthritis Rheumatol. 2022;74(11):1851\u20138.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"798_CR50","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s13075-018-1780-z","volume":"20","author":"J Swart","year":"2018","unstructured":"Swart J, Giancane G, Horneff G, Magnusson B, Hofer M, Alexeeva E, et al. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. Arthritis Res Ther. 2018;20(1):285.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"798_CR51","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13075-020-02167-2","volume":"22","author":"G Giancane","year":"2020","unstructured":"Giancane G, Swart JF, Castagnola E, Groll AH, Horneff G, Huppertz HI, et al. Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee. Arthritis Res Ther. 2020;22(1):71.","journal-title":"Arthritis Res Ther"},{"key":"798_CR52","unstructured":"Janssen Pharmaceutical Companies. Remicade (infliximab): Prescribing information.\u00a02020."},{"issue":"10","key":"798_CR53","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.3899\/jrheum.130133","volume":"40","author":"A Tambralli","year":"2013","unstructured":"Tambralli A, Beukelman T, Weiser P, Atkinson TP, Cron RQ, Stoll ML. High doses of infliximab in the management of juvenile idiopathic arthritis. J Rheumatol. 2013;40(10):1749\u201355.","journal-title":"J Rheumatol"},{"key":"798_CR54","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00798-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-023-00798-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00798-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T07:06:25Z","timestamp":1677222385000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-023-00798-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,24]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["798"],"URL":"https:\/\/doi.org\/10.1186\/s12969-023-00798-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2044092\/v1","asserted-by":"object"}]},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,24]]},"assertion":[{"value":"8 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GH declares serving on advisory boards and receiving research funds and honoraria from AbbVie, Chugai, GSK, MSD, Pfizer, Roche, and Sobi. KM declares serving on advisory boards and receiving honoraria from AbbVie, GSK, Novartis, Pfizer, Roche, and Sanofi. CR was an employee of Envision Pharma Group at the time the study was conducted and was a paid consultant to Pfizer in connection with the development of the manuscript. ACHD declares former employment with Pfizer, the sponsor of this systematic literature review, and holds stock and\/or stock options with Pfizer. CB is an employee of Pfizer and holds stock and\/or stock options with Pfizer. NR declares receiving honoraria for consultancies and serving on speakers bureaux for Ablynx, AstraZeneca-Medimmune, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, EMD Serono, GSK, Hoffmann-La Roche, Janssen, MSD, Novartis, Pfizer, R-Pharma, Sanofi, Servier, Sinergie, and Sobi; and is a full-time public employee of the IRCCS Istituto Giannina Gaslini that has received contributions from Bristol Myers Squibb, Eli Lilly, GSK, Hoffmann-La Roche, Janssen, Novartis, Pfizer, and Sobi, all of which have been invested in the research activities of the hospital in a fully independent manner and without any commitment to third parties.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}